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Abstract
There is growing evidence of shared risk alleles between complex traits (pleiotropy), including 
autoimmune and neuropsychiatric diseases. This might be due to sharing between all individuals 
(whole-group pleiotropy), or a subset of individuals within a genetically heterogeneous cohort 
(subgroup heterogeneity). BUHMBOX is a well-powered statistic distinguishing between these 
two situations using genotype data. We observed a shared genetic basis between 11 autoimmune 
diseases and type 1 diabetes (T1D, p<10−4), and 11 autoimmune diseases and rheumatoid arthritis 
(RA, p<10−3). This sharing was not explained by subgroup heterogeneity (corrected 
pBUHMBOX>0.2, 6,670 T1D cases and 7,279 RA cases). Genetic sharing between seronegative and 
seropostive RA (p<10−9) had significant evidence of subgroup heterogeneity, suggesting a 
subgroup of seropositive-like cases within seronegative cases (pBUHMBOX=0.008, 2,406 
seronegative RA cases). We also observed a shared genetic basis between major depressive 
disorder (MDD) and schizophrenia (p<10−4) that was not explained by subgroup heterogeneity 
(pBUHMBOX=0.28 in 9,238 MDD cases).
 INTRODUCTION
Recent studies have demonstrated that many diseases share risk alleles1–4 and exhibit 
significant coheritability5–7. Coheritability studies are defining the relationship between 
complex traits, and providing new insights into disease mechanisms. Critically, as the 
number of phenotypes studied with genetics expands in the context of emerging deeply 
phenotyped population-wide cohorts8, including the Precision Medicine Initiative9, 
coheritablity between traits will become even more apparent. In the genomic era, methods 
for detecting coheritability have moved beyond traditional approaches such as twin or family 
studies10, 11. Now, alternative approaches using genome-wide association study (GWAS) 
data from unrelated individuals are widely used. Polygenic risk score approaches3, 12, 13 
build genetic risk scores (GRSs) for one phenotype and test their association with a second 
phenotype. Mixed-model approaches5, 6, 14 can estimate the genetic covariance between two 
traits on the observed scale. Genetic covariance can be used to calculate genetic correlation 
and coheritability6. Cross-trait LD Score regression (LDSC) utilizes linkage disequilibrium 
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(LD) and summary statistics obtained from GWAS to estimate genetic correlation 
attributable to SNPs7. In addition, the p-values of independent SNPs associated with 
multiple phenotypes can be tested for a significant deviation from the null distribution2. 
These approaches have been applied to demonstrate significant shared genetic structure 
among many phenotypes5, 7, 15 including autoimmune2 and neuropsychiatric diseases3, 6, 13. 
The observed coheritability and genetic sharing suggests the possibility of pleiotropy, 
defined here as the sharing of risk alleles across traits at specific loci or at a genome-wide 
level. An example of pleiotropy is the PTPN22 variant R620W, which is associated with 
multiple autoimmune diseases16.
Shared risk alleles across diseases can be driven by all individuals or by a subset of 
individuals. In the former, the sharing is clearly driven by pleiotropy (whole-group 
pleiotropy). In the latter, only a subset of individuals is genetically similar to another 
disease. We call this subgroup heterogeneity – a situation where a patient cohort consists of 
genetically distinct subgroups that may or may not result in distinct symptom profiles and 
treatment outcomes. Subgroup heterogeneity can occur in the context of misclassifications 
(e.g. cases with atypical clinical presentations for a different disease are erroneously 
included), molecular subtypes (e.g. two different etiologies cause a disease, resulting in a 
subset of cases that share pathogenesis with a different disease), asymmetric causal 
relationships (e.g. one disease causes another disease, resulting in a subset of cases that also 
have the causal disease; often called mediated pleiotropy), or ascertainment bias (e.g. cases 
also affected with a different disease are more likely to come to clinical attention and be 
included in the study). These situations result in a subset of cases that is genetically similar 
to another disease, creating shared genetic structure17. Indeed, there is now evidence that 
misclassifications18–21, etiological diversity22, and ascertainment bias23 are prevalent across 
certain human diseases, leading to the conclusion that significant heterogeneity may 
exist24–27. Since the potential contribution of subgroup heterogeneity to any genetic sharing 
observed between diseases represents a critical disease insight, statistical methods are 
needed to distinguish subgroup heterogeneity from whole-group pleiotropy. For the purposes 
of this paper, we will use the term pleiotropy to refer to whole-group pleiotropy and 
heterogeneity to refer to subgroup heterogeneity.
 RESULTS
 Overview of BUHMBOX
Genetic sharing between disease A (DA) and disease B (DB) could be due to pleiotropy, but 
could also be due to heterogeneity (i.e. a subset of DA cases are genetically more similar to 
DB cases). If we calculated GRSs for DA cases using DB-associated loci and their effect 
sizes (GRSB), the mean of GRSB would be statistically different between DA cases and 
controls under either pleiotropy or heterogeneity. Under pleiotropy, some DB risk alleles 
impose DA risk, and DB risk alleles will be enriched in DA cases compared to controls. 
Under heterogeneity, a subset of DA cases will have genetic characteristics of DB, and 
therefore DB risk alleles will also be enriched in those individuals. In both situations, the 
enriched DB risk alleles in DA cases will result in an increased mean GRSB in individuals 
that are DA cases. For the same reasons, if we calculated the rg of DA and DB using cross-
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trait LDSC7 in this scenario, the rg would be positive under both pleiotropy and 
heterogeneity.
To detect heterogeneity, even in the presence of pleiotropy, we developed BUHMBOX 
(Breaking Up Heterogeneous Mixture Based On Cross-locus correlations). Our method tests 
for the presence of heterogeneous subgroups (i.e. DB-like cases) in an otherwise 
homogenous phenotype (i.e. DA). To do this, BUHMBOX requires (1) a list of known DB-
associated SNPs with corresponding risk alleles, risk allele frequencies, and effect sizes, and 
(2) individual-level genotype data for DB SNPs in DA cases. BUHMBOX leverages the fact 
that in the setting of heterogeneity, DB risk alleles have higher allele frequencies only in a 
specific subset of DA cases. In contrast, under true pleiotropy, DB risk alleles are expected to 
have higher allele frequencies across all DA cases (Figure 1). If DB risk alleles are enriched 
in one subgroup, the expected correlations of risk allele dosages between loci will be 
consistently positive (for details see Supplementary Table 1 and Supplementary Note). 
BUHMBOX combines these pairwise correlations into one statistic and tests for it; 
heterogeneity can lead to a significant BUHMBOX test statistic. In contrast, the lack of true 
heterogeneity or insufficient power to detect the presence of heterogeneity (type II error) can 
lead to a non-significant BUHMBOX test statistic. Insufficient power occurs when the 
number of DA cases, heterogeneity proportion, or number of known risk alleles and/or their 
effect sizes for DB are small.
 BUHMBOX discriminates between heterogeneity and pleiotropy
To demonstrate that BUHMBOX detects heterogeneity (even in the presence of pleiotropy), 
we conducted simulations with the following parameters: sample size of DA case individuals 
(N), number of risk loci associated to DB (M), and the proportion of DA cases that actually 
show genetic characteristics of DB (heterogeneity proportion, or π). To simulate realistic 
distributions of effect sizes and allele frequencies, we sampled odds ratio (OR) and risk 
allele frequency (RAF) pairs from reported associations in the GWAS catalog28 (Online 
Methods).
To characterize the false positive rate (FPR) of BUHMBOX we simulated 1,000,000 studies 
(N=2,000 and M=50) where there was no heterogeneity (π=0, Online Methods) or 
pleiotropy. BUHMBOX obtained a 5.1% FPR at p<0.05; it also obtained appropriate FPRs 
at a wide range of statistical significance thresholds (p<0.05 to 0.0005, Supplementary Table 
2).
To evaluate the FPR of BUHMBOX where there actually was pleiotropy without 
heterogeneity (π=0), we simulated 1,000 studies (N=2,000 and M=50) assuming DA and DB 
shared 10% of risk loci (five loci). We quantified the proportion of instances where 
BUHMBOX and GRS approaches obtained p-values smaller than the threshold p<0.05. GRS 
appropriately demonstrated 64.8% power to detect shared genetic structure. BUHMBOX 
demonstrated an appropriate false positive rate of 4.3% to detect heterogeneity 
(Supplementary Figure 1).
Finally, to evaluate BUHMBOX’s power to detect heterogeneity we repeated these 
simulations assuming there was no pleiotropy, but that there was indeed subtle 
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heterogeneity. We assumed that 10% of DA cases were actually DB (π=0.1). Here, 
BUHMBOX demonstrated 81.7% power to detect heterogeneity at p<0.05 (Supplementary 
Figure 1). The GRS approach demonstrated 100% power to detect shared genetic structure. 
Note that the power difference of the GRS approach in the pleiotropy and heterogeneity 
simulations is because of the stochastic chance that sampled effect sizes of all five loci may 
be small in the pleiotropy simulation; in simulations where we fixed the OR (1.25) and RAF 
(0.3) for all loci, the power of GRS was similar: 91.8% in pleiotropy and 92.0% in 
heterogeneity.
Together, these simulations illustrate that BUHMBOX is sensitive to heterogeneity but 
robust to pleiotropy, while the GRS detects both scenarios and cannot discriminate between 
the two. Thus, BUHMBOX complements methods for detecting pleiotropy by helping to 
interpret shared genetic structure (Supplementary Table 1).
 Weighting pairwise correlations increases power
BUHMBOX combines multiple pairwise correlations into one statistic. A pair of loci with 
larger allele frequencies and effect sizes will show larger expected correlation given the 
same π, and may be more informative than other pairs of loci (Supplementary Figure 2). We 
hypothesized that accounting for this unequal information between SNP pairs could increase 
power. We defined a scheme to weight pairwise correlations between loci as a function of 
their effect sizes and allele frequencies (Online Methods). In simulations we observed 
substantial power gain with this weighting scheme. Assuming 1,000 cases and 50 loci, we 
compared the BUHMBOX power implemented with and without weighting correlations 
(equation (12) in Supplementary Note). Across a wide range of π we observed that 
weighting dramatically increased power (Figure 2). For example, at π=0.1 the weighted 
implementation of BUHMBOX obtained 74% compared to the unweighted implementation 
which obtained only 36% power.
 Power is proportional to number of samples and loci
The statistical power of BUHMBOX is a function of many factors including sample size N 
of the cases we are testing for heterogeneity in, heterogeneity proportion π, number of loci 
M for the coheritable disease, RAF, and OR. We sampled pairs of RAF and OR from the 
GWAS catalog. Given a sample size of N=2,000 cases and 2,000 controls, assuming π=0.2 
and 50 risk loci, BUHMBOX achieved 92% power at p<0.05 (Figure 3). As many GWAS 
now consist of more than 2,000 cases, and many diseases are approaching 50 known 
associated loci28, BUHMBOX is currently well powered to detect a moderate amount 
heterogeneity (π=0.2) for many human traits. Modest heterogeneity is more challenging to 
detect at this sample size; power decreased to 67% at π=0.1 and to 38% at π=0.05. Power 
can be augmented with larger sample size (Figure 3) and larger effect sizes (Supplementary 
Figure 3). Power can also be increased by including large numbers of loci with even nominal 
evidence of association in addition to established genome-wide significant loci 
(Supplementary Note and Supplementary Figure 4).
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 Controlling for linkage disequilibrium
Although BUHMBOX adequately controlled the FPR when loci were truly independent, we 
were concerned that long-range LD between apparently independent loci may introduce 
false positives29. To ensure BUHMBOX was robust to LD, we implemented the following 
strategies: (1) stringent LD-pruning of DB loci to exclude SNPs with r2>0.1, and (2) 
accounting for any remaining residual LD by assessing the relative increase of correlations 
in cases compared to controls (delta-correlations). We evaluated these strategies by 
measuring FPR using the RA Immunochip Consortium data30. In 1,000 different loosely 
pruned (r2<0.5) SNP sets constructed using the Sweden EIRA data (Online Methods), the 
FPR without using delta-correlations was high (22.4% at p<0.05). Applying delta-
correlations reduced this FPR to 9.5%. When we used stringent pruning (r2<0.1), FPR was 
appropriately controlled (FPR 5.9% and FPR 5.3% with and without delta correlations, 
respectively). Although LD pruning alone was sufficiently effective for FPR control in this 
simulation, we used both strategies throughout the paper to be conservative.
 Accounting for population stratification
Another potential confounding factor is population stratification. If population stratification 
exists, weak correlations between unlinked loci may occur, leading to inappropriate 
significance. If similar population stratification exists in cases and controls, the use of delta-
correlations mitigates this effect. To more aggressively control for the effect of stratification 
at the individual level, we implemented BUHMBOX to regress out principal components 
(PCs) from risk allele dosages before calculating correlation statistics. To evaluate this 
strategy, we simulated extreme population stratification using HapMap31 data (60 CEU and 
60 YRI founders as cases, and 90 JPG+CHB founders as controls; λGC=26.5). 
Unsurprisingly, in 5,000 randomly sampled sets of independent SNPs we observed an 
inflated BUHMBOX FPR (14.1% at p<0.05). After regressing the effect of ten PCs from 
risk allele dosages, we observed that the FPR was appropriately controlled (5.7% at p<0.05). 
As an additional test under a more realistic scenario, we merged genotype data from 
Northern Europe (Sweden EIRA cohort; 2,762 cases/1,940 controls) and Southern Europe 
(Spain cohort; 807 cases/399 controls) in the RA Immunochip Consortium case-control 
dataset30 (Online Methods) to create a highly stratified dataset. In 1,000 sets of randomly 
sampled independent SNPs, we observed an inflation of the FPR (8.6% at p<0.05); this was 
appropriately corrected (5.9% at p<0.05) when we regressed out the effect of ten PCs.
 Application to autoimmune diseases
Autoimmune diseases share genetic loci2, 4, 32–36, clustering in specific immune 
pathways2, 27, 36. We used the GRS approach to evaluate shared genetic structure between 
autoimmune diseases, and then applied BUHMBOX to assess heterogeneity. We obtained 
individual-level genotype data from the Type 1 Diabetes Genetics Consortium (T1DGC) UK 
case-control cohort (6,670 cases and 9,416 controls)37 and the RA Immunochip 
Consortium’s six RA case-control cohorts (7,279 seropositive RA cases and 15,870 
controls)30 (Online Methods). We evaluated genetic sharing between a spectrum of 
autoimmune diseases with T1D and RA. We obtained associated independent loci for all 18 
autoimmune diseases (r2<0.1, including MHC SNPs) from ImmunoBase (see URLs and 
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Supplementary Table 3), and tested the association of GRSs for these autoimmune diseases 
with T1D and RA case status.
We observed substantial genetic sharing between autoimmune diseases. T1D demonstrated 
significant sharing with alopecia areata (AA), autoimmune thyroid disease (ATD), celiac 
disease (CEL), Crohn’s disease (CRO), juvenile idiopathic arthritis (JIA), primary biliary 
cirrhosis (PBC), primary sclerosing cholangitis (PSC), RA, Sjögren’s syndrome (SJO), 
systemic lupus erythematosus (SLE), and vitiligo (VIT) (positive association, p<10−4). RA 
exhibited significant sharing with AA, ankylosing spondylitis (AS), ATD, CEL, JIA, PBC, 
PSC, SLE, systemic sclerosis (SSC), T1D and VIT (p<10−3). Overall, GRSs showed 
significant positive associations for 11 autoimmune diseases each in T1D and RA cohorts, 
respectively (GRS p<2.9×10−3 [=0.05/17 correcting for 17 diseases tested]; Table 1, 
Supplementary Table 4). We considered only these traits for subsequent analyses.
To evaluate the degree of heterogeneity necessary to achieve the observed genetic sharing 
for these autoimmune diseases, we calculated the GRS regression coefficient, which we 
previously showed approximates the expected heterogeneity proportion π38 assuming no 
pleiotropy. Based on the GRS coefficients, we observed π estimates ranging from 0.08–0.76 
across the different autoimmune diseases in T1D and from 0.10–0.43 in RA (Figure 4, Table 
1).
We estimated the power of BUHMBOX to detect heterogeneity, correcting for 11 tests 
(p<4.5×10−3). BUHMBOX was well powered for some autoimmune traits; at π=0.2, four 
traits had >90% power for T1D, and four traits had >90% power for RA (Figure 5). Despite 
this, we observed no evidence of heterogeneity at all (corrected p>0.2; Figure 6, Table 1). 
Our findings suggest that autoimmune diseases share similar risk alleles and pathways with 
T1D and RA, and not by subgroups of genetically similar cases resulting from 
misclassifications or molecular subtypes.
 Application to subtype misclassifications in RA
RA consists of two subtypes, seropositive and seronegative, with distinct clinical outcomes 
and MHC associations38. These two subtypes are classified by whether patients are reactive 
to anti-CCP antibody. While anti-CCP testing is specific, its lack of sensitivity can result in 
some seropositive RA patients being misclassified as seronegative RA20. We previously 
demonstrated that there is shared genetic structure between seropositive and seronegative 
RA using the GRS approach38, which could imply misclassifications of up to 26.3% 
between the two RA subtypes.
We used BUHMBOX to evaluate whether seropositive RA misclassifications are present in a 
seronegative RA cohort. We used the seronegative RA cohort (2,406 cases/15,870 controls) 
from the RA Immunochip Consortium30. Among 68 RA-associated independent loci, we 
chose SNPs that are associated to seropositive RA (p<5×10−8) but not seronegative RA 
(p>5×10−8) in our Immunochip data. This criterion resulted in 14 specific loci exclusively 
associated to seropositive RA (Supplementary Table 3). The seropositive RA GRS was 
significantly associated with seronegative RA case status (β=0.30, p=1.1×10−10). The 
regression coefficient (β=0.30) represents an upper bound for π (Figure 4). BUHMBOX 
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suggested that heterogeneity was indeed present (p=0.008, Figure 6, Table 1, Supplementary 
Table 4), consistent with potential subtype misclassifications. As a more stringent test, we 
selected SNPs based on between-RA-subtype heterogeneity test results; for this test we 
obtained p-values by assigning seropositive RA as cases and seronegative RA as controls. 
We chose SNPs that are associated to seropositive RA (p<5×10−8) and show nominally 
significant between-RA-subtype heterogeneity (p<0.05, Supplementary Table 3). Applying 
BUHMBOX to these 12 loci still showed significant heterogeneity within the seronegative 
RA cohort (p=0.017).
 Application to major depressive disorder and schizophrenia
Current definitions of psychiatric disorders reflect clinical syndromes, with overlapping 
clinical features. As a result, psychiatric diagnoses for a patient may change as their 
symptoms evolve21. In addition to the potential for misdiagnosis, a subset of true MDD 
cases may be genetically more similar to schizophrenia. If heterogeneity with respect to 
schizophrenia risk alleles exists among MDD cases, then genetic studies would suggest 
evidence of coheritability between the two disorders17 as has been observed in previous 
studies3, 6, 7. The unintentional inclusion of “schizophrenia-like” MDD cases, due to 
diagnostic misclassification or genetically distinct subgroups, has been acknowledged and 
explored as a potential source of bias in coheritability studies by previous investigators3, 17.
We used BUHMBOX to test for a subgroup of “schizophrenia-like” cases in MDD. If a 
subset of MDD cases are misdiagnosed and in fact have schizophrenia, or are more 
genetically similar to schizophrenia, we would expect to see subgroup heterogeneity among 
MDD cases with respect to schizophrenia risk loci. We first evaluated evidence of shared 
genetic structure among 90 known schizophrenia associated loci39 (Supplementary Table 3) 
in 9,238 MDD cases and 7,521 controls from the Major Depressive Disorder Working Group 
of the Psychiatric Genomics Consortium40 (Supplementary Table 5). Consistent with 
previous findings (Supplementary Table 6)3, 6,7, the GRS was associated with MDD case 
status (p=1.54×10−5) indicating shared genetic structure (Figure 4). For the GRS analysis we 
used a refined subset of the total sample (6,382 MDD cases and 5,614 controls), excluding 
samples that overlapped with the schizophrenia GWAS39 (Online Methods). Application of 
cross-trait LDSC7 to estimate the genetic correlation obtained further evidence of shared 
genetic structure between MDD and SCZ (rg=0.47, SE=0.07, p=1.61×10−10), of similar 
magnitude to previous reports7. However, the BUHMBOX p-value was not significant 
(p=0.28), indicating no excess positive correlations among schizophrenia loci within MDD 
cases (Figure 6, Supplementary Table 4). Our findings suggest no evidence of a subgroup of 
schizophrenia-like MDD cases. However, we note that we lacked adequate statistical power 
to detect heterogeneity in the context of a small heterogeneity proportion. Given the MDD 
sample size and the number of currently known schizophrenia risk loci, there was 53% 
power at π=0.20 but only 25% power at π=0.10 (Figure 5).
 DISCUSSION
BUHMBOX can distinguish whether shared genetic structure between traits is the 
consequence of heterogeneity or pleiotropy based on SNP genotype data alone. It can help to 
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interpret recent observations of shared genetic structures in complex traits including 
autoimmune, neuropsychiatric, and metabolic diseases. The intuition behind BUHMBOX is 
that if heterogeneity exists, independent loci will show non-random positive correlations. 
Hence, correcting for population structure and long-range LD is critical for this approach to 
be effective. We emphasize that it is necessary to appropriately interpret the source of 
heterogeneity, which will depend on the biological and clinical relationship between the two 
traits. We provide detailed information to guide interpretation in the Supplementary Note.
We demonstrated that genetic sharing between autoimmune diseases is due to pleiotropy, 
noting that for a few traits we had only modest power (Figure 5). One notable exception was 
seronegative RA, which might contain misclassified seropositive RA cases. The results 
presented here demonstrate that seronegative RA is a heterogeneous phenotype with respect 
to genetic overlap with seropositive RA, bringing clarity to an ongoing debate about the 
nature of this disease. In contrast we were underpowered to draw more definitive 
conclusions as to whether a subset of MDD cases are genetically similar to schizophrenia 
cases; as MDD cohorts increase in size we will be able to reassess more accurately whether 
smaller proportions of heterogeneity might partially explain observed coheritability. Our 
results are consistent with recent analyses concluding that pleiotropy between psychiatric 
diseases is unlikely explained by misclassifications alone17.
We showed that the power of BUHMBOX is a function of sample size, heterogeneity 
proportion π, and the number, effect sizes and allele frequencies of loci. Power for subtle 
heterogeneity (π<0.1) in current datasets is limited. But, in future studies, increasing sample 
size and number of known associated loci will augment power. One potential strategy to 
augment power is to use a polygenic modeling3, 12, 13 approach, including a larger number 
of SNPs with less stringent significance thresholds (Supplementary Note and Supplementary 
Figure 4).
BUHMBOX has certain key caveats. First, it is designed to detect a specific type of 
heterogeneity resulting from the presence of a subgroup comprising a known second trait. 
Thus, BUHMBOX cannot currently be applied agnostically to detect the presence of 
heterogeneity within a dataset. Second, BUHMBOX requires prior knowledge of associated 
loci and their effect sizes. For diseases with few known loci, BUHMBOX may perform 
suboptimally. Also, if known effect size estimates are inaccurate, power may decrease 
because appropriate weighting is crucial (Figure 2). Third, BUHMBOX requires individual-
level genotype data for a limited number of loci. Fourth, BUHMBOX can be sensitive to 
confounding factors. We recommend careful control of LD and population structure using 
LD pruning and PCs. Fifth, interpretation of the BUHMBOX test statistic is not simplistic. 
Positive findings indicate the presence of heterogeneity but cannot distinguish between the 
various causes of this (e.g. misclassifications, molecular subtypes, mediated pleiotropy, 
ascertainment bias), and negative findings may indicate no heterogeneity or low power. To 
aid interpretation, BUHMBOX provides a power calculation based on sample size and risk 
allele information, but it may not always be accurate. For example, if pleiotropy and 
heterogeneity co-exist, power may be overestimated. Sixth, if the heterogeneity proportion π 
is small (e.g. 0.05), BUHMBOX’s ability to detect heterogeneity is limited. We expect that π 
will vary between situations, and further clinical and biological investigations are necessary 
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to uncover true π. Finally, there is the unlikely possibility that real epistasis can manifest as 
positive signal for BUHMBOX. Broadly, BUHMBOX can be thought of as capturing a 
specific form of epistasis where risk alleles correlate positively within the additive model. 
As such, if this specific form of epistasis occurs naturally between DB-associated SNPs, and 
if this epistasis structure is shared with DA, it has the potential to create a significant 
BUHMBOX test result and confound these analyses. However, this specific type of epistasis 
seems unlikely; were it present, application of BUHMBOX using DB-associated SNPs in DB 
cases to detect apparent “heterogeneity” might yield a significant result.
When comparing BUHMBOX to existing approaches, we focused on the GRS method. 
However, the results of our comparison also apply to other existing methods such as mixed-
model-based approaches5, 6 and LD-score-based approaches7, which are similar to the GRS 
approach in the sense that they detect both pleiotropy and heterogeneity. We expect that 
BUHMBOX will complement any of these methods to facilitate interpretation of observed 
genetic sharing between traits. Our statistical approach may be extended to have application 
beyond heterogeneity, including identification of missing heritability resulting from this type 
of heterogeneity41. These applications will become more feasible as functional annotations 
of SNPs advance in the coming years.
 ONLINE METHODS
 Genetic risk score approach
Given M independent risk loci associated to DB, we calculated the GRS of individual i as
where xij is individual i’s risk allele dosage at marker j, and βj is the effect size (log odds 
ratio) of risk allele at marker j for disease DB. The GRS approach calculates GRSs for all 
individuals and associates GRSs to the case/control status of DA. In the logistic regression 
framework for associating GRSs and DA status, we can obtain the regression coefficient for 
GRS (βGRS). We previously showed that βGRS approximates the proportion of DA cases that 
are genetically DB (heterogeneity proportion π), if we assume is no pleiotropy and the GRS 
association is solely driven by a subgroup38. Thus, βGRS represents an upper bound of π.
 The BUHMBOX approach
To detect heterogeneity within DA cases driven by a subgroup that is genetically similar to 
DB patients, we utilize the following procedure:
1. Prepare genotype data of DA cases and controls, and information about SNPs 
associated to DB (risk allele, RAF, and OR).
2. Prune SNPs associated to DB based on LD in control samples (excluding SNPs 
with r2>0.1 or within ±1Mb of other SNPs)
3. Obtain risk allele dosages of pruned SNPs from DA cases and controls
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4. Regress out PCs from risk allele dosages to obtain residual dosages, each locus 
at a time
5. Calculate R, the correlation matrix of residual dosages of risk alleles in N 
cases with DA and R′, in N′ controls
6. Calculate Y, a z-score matrix from delta-correlations:
7. Calculate the BUHMBOX statistic:
where yij is the element in Y at row i and column j. Given M pruned SNPs, (i,j) 
iterates M(M−1)/2 non-diagonal elements of Y. The wij term is a weighting 
function that is designed to maximize power, such that (equation (13) in 
Supplementary Note):
where pi is RAF of SNP i, and γi is the OR of SNP i for DB. The BUHMBOX 
statistic follows N(0,1) under the null hypothesis. We calculate the significance 
of this statistic as a positive one-sided test; the p-value is pBUHMBOX = 1 − 
Φ(SBUHMBOX) where Φ is the cumulative density function of the standard 
normal distribution. In the context of heterogeneity, excessive positive 
correlations among DB risk alleles in DA cases result in pBUHMBOX < α. See 
Supplementary Table 1 for a comparison of BUHMBOX and GRS approaches. 
The BUHMBOX test statistic was inspired by previous work deriving 
covariance between correlation estimates42 and on combining dependent 
estimates43, 44. For details of the intuition, derivation, optimization, and 
interpretation of the BUHMBOX test statistic, see Supplementary Note.
 Code availability
BUHMBOX has been fully implemented as a publicly available R script (see URLs).
 Power and false positive rate simulations
Given sample size of DA cases (N), proportion of DA cases that actually show genetic 
characteristics of DB (heterogeneity proportion π), and number of risk loci associated to DB 
(M), we simulated studies to estimate power of our method as follows. To simulate a 
reasonable joint distribution of RAFs and ORs, we downloaded the GWAS catalog (as of 29 
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April 2014). Among all binary traits in the catalog, we selected traits with ≥50 reported 
SNPs resulting in 22 traits with 1,480 SNPs. From these SNPs, we sampled M pairs of RAF 
(p) and their corresponding OR (γ). To simulate genotypes, we set the RAF of a subgroup 
(Nπ individuals) to γp/((γ−1)p+1) and p for the other subgroup (N(1−π) individuals), 
because Nπ individuals can be thought of as DB cases. Within each subgroup, we generated 
genotypes assuming that risk alleles are distributed according to the Hardy-Weinberg 
equilibrium (HWE) and risk loci are independent. We assumed HWE in cases because we 
assumed an additive disease model. Then we applied BUHMBOX to calculate the p-value. 
We repeated this 1,000 times to approximate power as the proportion of simulations with p-
values ≤0.05. We evaluated power for different values of N, M, and π.
Under the assumption that the loci are independent, the FPR simulation was equivalent to 
the power simulation described above with the only difference being that π was set to zero, 
which forced the null hypothesis. We measured the FPR by assuming N=1,000 and M=20, 
and constructing 1,000,000 such studies.
 Linkage disequilibrium simulations
To simulate realistic LD, we used chromosome 22 data from control individuals in the 
Swedish EIRA cohort of the RA dataset (2,762 cases/1,940 controls)30. We assigned half of 
control individuals as cases and the rest as controls. To generate 1,000 random sets of SNPs, 
we began from all SNPs and thinned the SNP set by 10-fold with different seed numbers 
using PLINK45 (with the command --thin 0.1). We then pruned each of the 1,000 datasets 
using PLINK45 with r2 criterion of 0.5 or 0.1.
 Population stratification simulations
To assess the effects of population stratification, we conducted two sets of simulations. First, 
used data from HapMap31 release 23 data (60 CEU founders, 60 YRI founders, and 90 JPT
+CHB founders) setting CEU+YRI as cases and JPT+CHB as controls. We calculated PCs 
after LD pruning (r2<0.1). For DB SNPs we randomly selected 5,000 sets of 22 independent 
SNPs; we selected a single SNP from each autosome. Second, we used genotype data from a 
Northern Europe RA cohort (Swedish EIRA; 2,762 cases/1,940 controls) and a Southern 
Europe cohort (Spain; 807 cases/399 controls) from the RA dataset30. For this simulation we 
used SNPs that we had generated for LD simulations (described above, thinned from 
Swedish EIRA chromosome 22 with criterion r2<0.1), by setting them as cases and adding 
Spain samples as controls.
 Application to specific phenotypes
 Type 1 diabetes dataset—To evaluate pleiotropy and heterogeneity between 18 
autoimmune diseases and T1D, we applied GRS and BUHMBOX approaches to the UK 
case-control dataset provided by the T1DGC37, which consisted of a total of 16,086 samples 
(6,670 cases and 9,416 controls) from three collections: (1) cases from the UK-GRID, (2) 
shared controls from the British 1958 Birth Cohort and (3) shared controls from Blood 
Services controls (data release 4 February 2012, hg18). The samples were collected from 13 
regions. All samples were collected after obtaining informed consent, and were genotyped 
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on the Immunochip array. GRS and BUHMBOX analyses were conducted using the region 
index as covariates.
 Rheumatoid arthritis dataset—To evaluate pleiotropy and heterogeneity between 18 
autoimmune diseases and RA, we used the RA Immunochip consortium data from six RA 
case-control cohorts (UK, US, Dutch, Spanish, Swedish Umea, and Swedish EIRA)30. To 
evaluate pleiotropy to autoimmune diseases, we used 7,279 seropositive RA cases and 
15,870 controls. To evaluate misclassifications of RA subtypes, we used 2,406 seronegative 
RA samples and the same controls. Seropositive and seronegative RA patients were defined 
in each cohort using standard clinical practices to assess whether patients were reactive to 
anti-CCP antibody38. All samples were obtained with informed consent, and were collected 
through institutional review board approved protocols. All individuals self-reported as white 
and of European descent. Samples were genotyped with the Immunochip array. We merged 
the data of six cohorts into one, and used binary variables representing cohorts as well as 10 
PCs as covariates in the analysis.
 Defining autoimmune risk loci—We accessed ImmunoBase (7 June 2015 version) to 
define genome-wide significant risk loci for 18 autoimmune diseases. We did not include 
inflammatory bowel disease, due to its redundancy with Crohn’s disease and ulcerative 
colitis. For each of the 18 autoimmune diseases analyzed we pruned the list of index SNPs 
obtained from ImmunoBase in PLINK45 with options --r2 --ld-window-r2 0.1, using the 
1000 Genomes Phase 1 European reference panel for LD. For all pairs of SNPs with r2>0.1, 
we kept the most strongly associated SNP. To ensure completely independent risk loci we 
also removed SNPs annotated as being located in the same chromosomal region in 
ImmunoBase, again keeping the most strongly associated index SNP (Supplementary Table 
3). When a locus was not in the Immunochip datasets, we looked for a proxy (r2>0.2) based 
on the 1000 Genomes data.
 Major depressive disorder dataset—We used BUHMBOX to investigate the 
relationship between MDD and schizophrenia, which have been previously reported to share 
genetic etiology based on polygenic risk scoring3 and coheritability analyses6. The full 
MDD sample analyzed comprised nine GWAS datasets collected from eight separate studies 
(Supplementary Table 5) as previously described40. All samples were collected through 
institutional review board approved protocols and were obtained with informed consent. 
Independence of the training (SCZ) and target (MDD) datasets is crucial in GRS analyses; 
GRSs are constructed using effect size estimates obtained using allele frequency differences 
between cases and controls in the training GWAS, and overlapping cases or controls will 
therefore bias the association of GRSs to the target dataset in the positive direction. In 
contrast the BUHMBOX test statistic is based on the correlation of risk allele dosages 
among cases, which is orthogonal to allele frequency differences in cases and controls, and 
is therefore not inflated by sample overlap. Thus, for the GRS analysis individual MDD 
samples (four cases, 886 controls) that overlapped with those in the schizophrenia GWAS39 
were removed from the analysis; three GWAS cohorts with an insufficient number of 
independent control samples (N<5) were also removed from the analysis. GRS analyses 
were conducted in each of the remaining six GWAS datasets (Supplementary Table 5), 
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followed by meta-analysis of the GRS. To obtain the overall GRS effect size (β) and test 
statistic we used the inverse-variance weighted fixed effects method. For BUHMBOX, we 
used the full dataset; analyses were conducted in each of the nine GWAS datasets 
(Supplementary Table 5) followed by meta-analysis. Because the BUHMBOX statistic is a 
z-score, we meta-analyzed BUHMBOX results across the datasets using the standard 
weighted sum of z-score approach, where z-scores are weighted by the square root of the 
sample size.
 Defining schizophrenia risk loci—Schizophrenia associated SNPs were selected as 
those showing genome-wide significant association with schizophrenia (p<5×10−8) in the 
most recent Psychiatric Genomics Consortium39 GWAS. For schizophrenia associated SNPs 
not directly genotyped in the MDD GWAS datasets, we selected proxy SNPs as those with 
the highest r2 from the list of all proxies with r2>0.2 using the 1000 Genomes Phase 1 
European reference panel. Of the 97 schizophrenia associated SNPs (11 indels were not 
considered in our analysis), 90 LD-independent SNPs (r2>0.1, distance to each other is 
>1Mb) were available for analysis in the MDD GWAS datasets either via direct genotyping 
or by a proxy SNP (see Supplementary Table 3 for a detailed list of SNPs).
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
 Acknowledgments
This work is supported in part by funding from the National Institutes of Health (1R01AR063759 (SR), 
1R01AR063759-01A1 (SR), 1UH2AR067677-01 (SR), U19 AI111224-01 (SR)) and the Doris Duke Charitable 
Foundation Grant #2013097. BH is supported by the Asan Institute for Life Sciences, Asan Medical Center, Seoul, 
Korea (2016-0717) and the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of 
Korea (HI14C1731). JGP is supported by Fulbright Canada, the Weston Foundation, and by Brain Canada through 
the Canada Brain Research Fund. KS is supported by an NIH training grant (T32 HG002295). NRW is supported 
by the Australian National Health and Medical Research Council (1087889, 1078901). This research utilizes 
resources provided by the Type 1 Diabetes Genetics Consortium, a collaborative clinical study sponsored by the 
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Allergy and 
Infectious Diseases (NIAID), National Human Genome Research Institute (NHGRI), National Institute of Child 
Health and Human Development (NICHD), and Juvenile Diabetes Research Foundation International (JDRF) and 
supported by U01 DK062418.
REFERENCES FOR MAIN TEXT
1. Sivakumaran S, et al. Abundant pleiotropy in human complex diseases and traits. Am J Hum Genet. 
2011; 89:607–618. [PubMed: 22077970] 
2. Cotsapas C, et al. Pervasive sharing of genetic effects in autoimmune disease. PLoS Genet. 2011; 
7:e1002254. [PubMed: 21852963] 
3. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with 
shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013; 
381:1371–1379. [PubMed: 23453885] 
4. Fortune MD, et al. Statistical colocalization of genetic risk variants for related autoimmune diseases 
in the context of common controls. Nat Genet. 2015; 47:839–846. [PubMed: 26053495] 
5. Lee SH, Yang J, Goddard ME, Visscher PM, Wray NR. Estimation of pleiotropy between complex 
diseases using single-nucleotide polymorphism-derived genomic relationships and restricted 
maximum likelihood. Bioinformatics. 2012; 28:2540–2542. [PubMed: 22843982] 
Han et al. Page 14
Nat Genet. Author manuscript; available in PMC 2016 November 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
6. Cross-Disorder Group of the Psychiatric Genomics Consortium. Genetic relationship between five 
psychiatric disorders estimated from genome-wide SNPs. Nat Genet. 2013; 45:984–994. [PubMed: 
23933821] 
7. Bulik-Sullivan B, et al. An atlas of genetic correlations across human diseases and traits. Nat Genet. 
2015; 47:1236–1241. [PubMed: 26414676] 
8. Pendergrass SA, et al. Phenome-wide association study (PheWAS) for detection of pleiotropy within 
the Population Architecture using Genomics and Epidemiology (PAGE) Network. PLoS Genet. 
2013; 9:e1003087. [PubMed: 23382687] 
9. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015; 372:793–795. 
[PubMed: 25635347] 
10. Criswell LA, et al. Analysis of families in the multiple autoimmune disease genetics consortium 
(MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. 
Am J Hum Genet. 2005; 76:561–571. [PubMed: 15719322] 
11. Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ. Major depression and generalized 
anxiety disorder. Same genes, (partly) different environments? Arch Gen Psychiatry. 1992; 
49:716–722. [PubMed: 1514877] 
12. Wray NR, Goddard ME, Visscher PM. Prediction of individual genetic risk to disease from 
genome-wide association studies. Genome Res. 2007; 17:1520–1528. [PubMed: 17785532] 
13. Purcell SM, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar 
disorder. Nature. 2009; 460:748–752. [PubMed: 19571811] 
14. Lee SH, et al. New data and an old puzzle: the negative association between schizophrenia and 
rheumatoid arthritis. Int J Epidemiol. 2015; 44:1706–21. [PubMed: 26286434] 
15. Power RA, et al. Polygenic risk scores for schizophrenia and bipolar disorder predict creativity. Nat 
Neurosci. 2015; 18:953–955. [PubMed: 26053403] 
16. Solovieff N, Cotsapas C, Lee PH, Purcell SM, Smoller JW. Pleiotropy in complex traits: challenges 
and strategies. Nat Rev Genet. 2013; 14:483–495. [PubMed: 23752797] 
17. Wray NR, Lee SH, Kendler KS. Impact of diagnostic misclassification on estimation of genetic 
correlations using genome-wide genotypes. Eur J Hum Genet. 2012; 20:668–674. [PubMed: 
22258521] 
18. Silverberg MS, et al. Diagnostic misclassification reduces the ability to detect linkage in 
inflammatory bowel disease genetic studies. Gut. 2001; 49:773–776. [PubMed: 11709510] 
19. van der Linden MP, et al. Value of anti-modified citrullinated vimentin and third-generation anti-
cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and 
rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid 
arthritis. Arthritis Rheum. 2009; 60:2232–2241. [PubMed: 19644872] 
20. Wiik AS, van Venrooij WJ, Pruijn GJ. All you wanted to know about anti-CCP but were afraid to 
ask. Autoimmun Rev. 2010; 10:90–93. [PubMed: 20727426] 
21. Bromet EJ, et al. Diagnostic shifts during the decade following first admission for psychosis. Am J 
Psychiatry. 2011; 168:1186–1194. [PubMed: 21676994] 
22. Gibson P, et al. Subtypes of medulloblastoma have distinct developmental origins. Nature. 2010; 
468:1095–1099. [PubMed: 21150899] 
23. Smoller JW, Lunetta KL, Robins J. Implications of comorbidity and ascertainment bias for 
identifying disease genes. Am J Med Genet. 2000; 96:817–822. [PubMed: 11121189] 
24. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic 
heterogeneity in cancer evolution. Nature. 2013; 501:338–345. [PubMed: 24048066] 
25. Jeste SS, Geschwind DH. Disentangling the heterogeneity of autism spectrum disorder through 
genetic findings. Nat Rev Neurol. 2014; 10:74–81. [PubMed: 24468882] 
26. Flint J, Kendler KS. The genetics of major depression. Neuron. 2014; 81:484–503. [PubMed: 
24507187] 
27. Cho JH, Feldman M. Heterogeneity of autoimmune diseases: pathophysiologic insights from 
genetics and implications for new therapies. Nat Med. 2015; 21:730–738. [PubMed: 26121193] 
28. Welter D, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic 
Acids Res. 2014; 42:D1001–6. [PubMed: 24316577] 
Han et al. Page 15
Nat Genet. Author manuscript; available in PMC 2016 November 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
29. Raychaudhuri S, et al. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with 
rheumatoid arthritis risk. Nat Genet. 2009; 41:1313–1318. [PubMed: 19898481] 
30. Eyre S, et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid 
arthritis. Nat Genet. 2012; 44:1336–1340. [PubMed: 23143596] 
31. The International HapMap Consortium. The International HapMap Project. Nature. 2003; 
426:789–796. [PubMed: 14685227] 
32. Smyth DJ, et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J 
Med. 2008; 359:2767–2777. [PubMed: 19073967] 
33. Festen EA, et al. A meta-analysis of genome-wide association scans identifies IL18RAP, PTPN2, 
TAGAP, and PUS10 as shared risk loci for Crohn’s disease and celiac disease. PLoS Genet. 2011; 
7:e1001283. [PubMed: 21298027] 
34. Zhernakova A, et al. Meta-analysis of genome-wide association studies in celiac disease and 
rheumatoid arthritis identifies fourteen non-HLA shared loci. PLoS Genet. 2011; 7:e1002004. 
[PubMed: 21383967] 
35. Jostins L, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory 
bowel disease. Nature. 2012; 491:119–124. [PubMed: 23128233] 
36. Cotsapas C, Hafler DA. Immune-mediated disease genetics: the shared basis of pathogenesis. 
Trends Immunol. 2013; 34:22–26. [PubMed: 23031829] 
37. Onengut-Gumuscu S, et al. Fine mapping of type 1 diabetes susceptibility loci and evidence for 
colocalization of causal variants with lymphoid gene enhancers. Nat Genet. 2015; 47:381–386. 
[PubMed: 25751624] 
38. Han B, et al. Fine mapping seronegative and seropositive rheumatoid arthritis to shared and distinct 
HLA alleles by adjusting for the effects of heterogeneity. Am J Hum Genet. 2014; 94:522–532. 
[PubMed: 24656864] 
39. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 
108 schizophrenia-associated genetic loci. Nature. 2014; 511:421–427. [PubMed: 25056061] 
40. Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium. A mega-
analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry. 2013; 
18:497–511. [PubMed: 22472876] 
41. Wray NR, Maier R. Genetic basis of complex genetic disease: The contribution of disease 
heterogeneity to missing heritability. Curr Epidemiol Rep. 2014; 1:220–227.
42. Jennrich RI. An asymptotic χ2 test for the equality of two correlation matrices. J Am Statist Assoc. 
1970; 65:904–912.
43. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by 
modeling marginal distributions. J Am Statist Assoc. 1989; 84:1065–1073.
44. Lin DY, Sullivan PF. Meta-analysis of genome-wide association studies with overlapping subjects. 
Am J Hum Genet. 2009; 85:862–872. [PubMed: 20004761] 
45. Purcell S, et al. PLINK: a tool set for whole-genome association and population-based linkage 
analyses. Am J Hum Genet. 2007; 81:559–575. [PubMed: 17701901] 
Han et al. Page 16
Nat Genet. Author manuscript; available in PMC 2016 November 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. Overview of BUHMBOX
(a) Under the scenario of subgroup heterogeneity, risk alleles of disease B (DB)-associated 
loci will be enriched in a subgroup of disease A (DA) cases, producing positive correlations 
between DB risk allele dosages from independent loci. (b) Under the scenario where there is 
no heterogeneity and DA and DB share alleles due to pleiotropy (i.e. whole-group 
pleiotropy), DB risk alleles will be uniformly distributed and have no correlations. Red 
boxes: risk alleles; white boxes: non-risk alleles.
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Figure 2. Power gain by weighting SNPs by allele frequency and effect size
We compared the statistical power of BUHMBOX with a weighting scheme that optimally 
weights correlations between SNPs (weighted) to an alternative approach that weights 
correlations uniformly (unweighted; equation (12) in Supplementary Note). We simulated 
1,000 case individuals and assumed 50 risk loci, whose OR and RAFs were sampled from 
the GWAS catalog. Colored bands denote 95% confidence intervals of power estimates.
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Figure 3. BUHMBOX power analysis
Power of BUHMBOX for detecting heterogeneity as a function of the number of risk loci, 
number of case samples, and the proportion of samples that actually have different 
phenotype (heterogeneity proportion, π). We assume that we have the same number of 
controls as cases. White lines denote 20, 40, 60, and 80% power. (a) Power as a function of 
number of case individuals and heterogeneity proportion, when the number of risk loci is 
fixed at 50. (b) Power as a function of number of risk loci and heterogeneity proportion, 
when the case sample size is fixed at 2,000.
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Figure 4. Genetic sharing between autoimmune diseases and psychiatric disorders
In (a) and (b), we show only the diseases that have significantly positive GRS p-values out 
of the 17 tested. Y-axis denotes the expected heterogeneity proportion (π) to explain 
observed genetic sharing. Vertical bars indicate 95% confidence intervals. Heterogeneity 
proportion estimates are based on GRS analysis, assuming no pleiotropy for (a) T1D, (b) 
RA, (c) seronegative RA, and (d) MDD.
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Figure 5. Statistical power of BUHMBOX to detect heterogeneity
We calculated power by performing 1,000 simulations with corresponding sample size, 
number of risk alleles, risk allele frequencies, and odds ratios. To calculate power for (c) and 
(d), we used a significance threshold of 0.05. For (a) and (b), the threshold was adjusted 
using the Bonferroni correction accounting for 11 tests in T1D and RA, respectively.
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Figure 6. BUHMBOX results
We show only diseases with significantly positive GRS p-values (for complete results for all 
traits tested, see Supplementary Table 4). Significant GRS p-values indicate evidence of 
shared genetic structure; significant BUHMBOX p-value indicates evidence of 
heterogeneity. Point size represents the number of DB-associated SNPs included in the 
analysis. Dashed vertical lines denote the Bonferroni-adjusted significance threshold for the 
BUHMBOX test statistic. Arrow indicates significant BUHMBOX test statistic.
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